Slingshot members are tracking this event:

AbbVie Receives FDA Accelerated Approval of Venclexta (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details - Novel BCL-2 inhibitor, approved as a single agent, provided 80 percent overall response rate in Phase 2 clinical study in patients with 17p deletion(1)
- Important new treatment option for patients with difficult to treat form of CLL(2)
- The approval of Venclexta reinforces AbbVie's growing position in hematologic oncology
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Venclexta, Venetoclax, Bcl-2 Inhibitor, Chronic Lymphocytic Leukemia Patients